检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:刘玉[1] 邓建华 LIU Yu;DENG Jianhua(Jiujiang First People’s Hospital,Jiangsuxi Jiujiang 332000,China)
机构地区:[1]江西省九江市第一人民医院,江西九江332000
出 处:《中医药临床杂志》2023年第6期1210-1214,共5页Clinical Journal of Traditional Chinese Medicine
摘 要:目的:探讨淫羊藿配方颗粒治疗晚期恶性肿瘤患者癌因性疲乏的效果。方法:选择2021年7月—2022年12月收治的108例晚期恶性肿瘤患者,按随机数字表法均分为对照组与试验组,对照组运动疗法,试验组在对照组基础上加用淫羊藿配方颗粒干预。2组均连续干预3周。比较2组Piper疲乏修订量表(PFS-R)评分、生存质量(EORTC QLQ-C30)评分、焦虑评分(HAMA-14)、抑郁评分(HAMD-17)。结果:干预后,2组PFS-R评分、HAMA-14评分、HAMD-17评分均降低(P<0.05),试验组均低于对照组(P<0.05);2组EORTC QLQ-C30各项评分均升高,试验组均高于对照组(P<0.05)。结论:淫羊藿配方颗粒应用于晚期恶性肿瘤患者癌因性疲乏效果显著,可缓解负性情绪及疲乏程度,提升生活质量。Objective:To investigate the efficacy of Epimedium Formula Granules in the treatment of cancer related fatigue in patients with advanced malignant tumors.Methods:A total of 108 patients with advanced malignant tumors admitted from July 2021 to December 2022 were randomly divided into two groups.The control group and experimental group.The control group received exercise therapy,and the experimental group received intervention with Epimedium Formula Granules on the basis of the control group.Both groups were continuously intervened for 3 weeks.The scores of Piper Fatigue Revised Scale(PFS-R),Quality of Life(EORTC QLQ-C30),Anxiety Score(HAMA-14),and Depression Score(HAMD-17)were compared between the two groups.Results:After intervention,the PFS-R score,HAMA-14 score,and HAMD-17 score in both groups decreased(P<0.05),and the test group were lower(P<0.05),the EORTC QLQ-C30 scores in both groups increased(P<0.05),and the test group was higher(P<0.05).Conclusion:The application of Epimedium Formula Granules in the treatment of cancer related fatigue in patients with advanced malignant tumors has a significant effect,can alleviate negative emotions and fatigue levels,and improve quality of life.
关 键 词:恶性肿瘤 癌因性疲乏 运动疗法 淫羊藿配方颗粒 生活质量
分 类 号:R273[医药卫生—中西医结合]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3